Published in Nature on September 30, 2010
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
From vaccines to memory and back. Immunity (2010) 3.30
Antibodies in HIV-1 vaccine development and therapy. Science (2013) 3.13
Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 3.04
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell (2014) 2.36
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature (2014) 2.33
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest (2011) 2.14
Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A (2012) 2.13
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med (2012) 2.12
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99
A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J Exp Med (2011) 1.97
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol (2012) 1.86
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell (2016) 1.82
Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS One (2011) 1.69
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med (2013) 1.68
Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell (2016) 1.57
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell (2015) 1.54
Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol (2011) 1.51
Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology (2011) 1.48
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell (2015) 1.46
High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. PLoS One (2015) 1.45
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol (2012) 1.39
Harnessing CD4⁺ T cell responses in HIV vaccine development. Nat Med (2013) 1.39
Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med (2013) 1.31
Tools to therapeutically harness the human antibody response. Nat Rev Immunol (2012) 1.30
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses (2011) 1.30
Anti-HIV B Cell lines as candidate vaccine biosensors. J Immunol (2012) 1.28
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity (2016) 1.26
Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J Clin Invest (2012) 1.25
Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol (2012) 1.23
A Temporal Model of Human IgE and IgG Antibody Function. Front Immunol (2013) 1.23
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest (2014) 1.19
Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A (2012) 1.18
Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol (2014) 1.15
Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells. Proc Natl Acad Sci U S A (2011) 1.14
Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol (2011) 1.13
Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol (2011) 1.12
B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med (2010) 1.11
Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat Med (2011) 1.10
Evolving concepts of specificity in immune reactions. Proc Natl Acad Sci U S A (2010) 1.09
Progress in HIV-1 vaccine development. Curr Opin HIV AIDS (2013) 1.09
Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med (2015) 1.06
Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J Virol (2010) 1.04
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One (2011) 1.03
Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell (2015) 1.02
AIDS/HIV. Host controls of HIV neutralizing antibodies. Science (2014) 1.00
Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. J Infect Dis (2012) 0.98
Human B-1 cells take the stage. Ann N Y Acad Sci (2013) 0.97
Antigenic properties of the HIV envelope on virions in solution. J Virol (2013) 0.97
Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc Natl Acad Sci U S A (2013) 0.97
A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition. PLoS Pathog (2013) 0.97
The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation. J Exp Med (2013) 0.97
Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients. Nat Commun (2014) 0.96
How specific is too specific? B-cell responses to viral infections reveal the importance of breadth over depth. Immunol Rev (2013) 0.96
Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS (2014) 0.95
Regulation of mucosal IgA responses: lessons from primary immunodeficiencies. Ann N Y Acad Sci (2011) 0.95
Human B-cell ontogeny in humanized NOD/SCID γc(null) mice generates a diverse yet auto/poly- and HIV-1-reactive antibody repertoire. Genes Immun (2012) 0.94
Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions. J Virol (2011) 0.94
BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J Immunol (2012) 0.93
Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. J Virol (2012) 0.93
Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. PLoS One (2012) 0.93
Central B-cell tolerance: where selection begins. Cold Spring Harb Perspect Biol (2012) 0.92
Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol (2013) 0.91
Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject. PLoS One (2012) 0.91
B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. J Immunol (2013) 0.91
A critical question for HIV vaccine development: which antibodies to induce? Science (2014) 0.91
Antigen-driven induction of polyreactive IgM during intracellular bacterial infection. J Immunol (2012) 0.91
Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol (2011) 0.91
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother (2011) 0.90
Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host Microbe (2013) 0.90
Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum (2013) 0.89
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med (2016) 0.87
HIV: Roadmaps to a vaccine. Nature (2013) 0.87
Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion. Biophys J (2014) 0.87
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathog (2015) 0.87
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunol Lett (2012) 0.86
Cross-reactive broadly neutralizing antibodies: timing is everything. Front Immunol (2012) 0.86
Progress toward active or passive HIV-1 vaccination. J Exp Med (2016) 0.86
Clonal redemption of autoantibodies by somatic hypermutation away from self-reactivity during human immunization. J Exp Med (2016) 0.86
Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory. Immunity (2016) 0.85
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog (2014) 0.85
Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? Expert Rev Vaccines (2014) 0.85
Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies. AIDS (2011) 0.85
Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology (2014) 0.85
Structural basis for germline antibody recognition of HIV-1 immunogens. Elife (2016) 0.84
Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of anergy. Mol Immunol (2010) 0.84
Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses. PLoS One (2013) 0.84
Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa. PLoS One (2014) 0.84
Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines (Basel) (2013) 0.83
Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies. PLoS One (2014) 0.83
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses (1994) 6.35
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A (1991) 6.13
Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods (2007) 5.97
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med (2005) 4.16
Autoreactivity in human IgG+ memory B cells. Immunity (2007) 3.71
Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol (2004) 3.69
Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature (2005) 3.55
A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med (2006) 2.60
A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods (2008) 2.56
Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med (1994) 2.44
Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J Exp Med (2003) 2.09
Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A (2009) 1.74
Virus-induced autoantibody response to a transgenic viral antigen. Nature (1990) 1.42
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
HIV/AIDS: allied responses. Nature (2007) 1.28
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J Virol (1996) 1.22
Molecular structure of eight human autoreactive monoclonal antibodies. Immunology (2001) 1.19
The strange cross-reaction of menadione (vitamin K3) and 2,4-dinitrophenyl ligands with a myeloma protein and some conventional antibodies. J Exp Med (1974) 1.13
Modulation of nuclear receptor interactions by ligands: kinetic analysis using surface plasmon resonance. Biochemistry (1996) 1.09
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
Genomic instability in mice lacking histone H2AX. Science (2002) 10.23
Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol (2005) 9.91
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 8.42
Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Visualizing dendritic cell networks in vivo. Nat Immunol (2004) 7.13
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity (2007) 6.66
Visualization of the intracellular behavior of HIV in living cells. J Cell Biol (2002) 6.59
Advances in methods and algorithms in a modern quantum chemistry program package. Phys Chem Chem Phys (2006) 6.51
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol (2006) 6.30
Germinal centers. Annu Rev Immunol (2012) 6.26
Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science (2003) 6.22
Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A (2002) 6.19
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature (2008) 6.17
Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods (2007) 5.97
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell (2010) 5.49
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS (2003) 5.28
Direct observation of ligand recognition by T cells. Nature (2002) 5.21
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity (2008) 5.03
The immunological synapse balances T cell receptor signaling and degradation. Science (2003) 4.94
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol (2008) 4.52
Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J Exp Med (2004) 4.52
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37
Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science (2011) 4.30
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity (2005) 4.22
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet (2005) 4.21
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med (2005) 4.16
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell (2008) 4.13
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science (2008) 4.11
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature (2006) 3.90
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90